Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644338 | 0.91 | NR1H4 (0.48) | PDE2APPARGALDH1A1LMNANR1H4 | |
| SCHEMBL1644385 | 0.87 | MAOB (0.43) | PDE2ADDR2 | |
| SCHEMBL1285062 | 0.85 | PTPN1 (0.44) | PDE2ADDR2NPSR1PTGER4 | |
| SCHEMBL1643666 | 0.84 | PDE2A (0.39) | PDE2ADDR2ALDH1A1LMNARORC | |
| SCHEMBL1642830 | 0.84 | PDE2A (0.46) | PDE2A | |
| SCHEMBL1645409 | 0.84 | PDE2A (0.44) | PDE2APPARGNPSR1 | |
| SCHEMBL1644914 | 0.83 | PDE2A (0.45) | PDE2APPARGNPSR1CYP3A4 | |
| SCHEMBL1644853 | 0.83 | PDE2A (0.43) | PDE2ADDR2NPSR1CYP3A4RORC | |
| SCHEMBL1285051 | 0.82 | TRPV1 (0.42) | PDE2ADDR2PTGER4 | |
| SCHEMBL1644118 | 0.80 | RORC (0.36) | PDE2ADDR2ALDH1A1LMNARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | PDE2A 1116/4885DDR2 2428/4885PPARG 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.